二线治疗-话题@MedSci

#二线治疗#

120篇内容 | 3340人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1543887, encodeId=a56f154388e00, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=WCLC 2013：EGFR野生型NSCLC二线治疗中培美曲塞优于吉非替尼（CTONG 0806研究）, objectType=article, longId=26015, objectId=e591260152f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e591260152f, replyNumber=0, likeNumber=54, createdTime=2013-11-01, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e591260152f, moduleTitle=WCLC 2013：EGFR野生型NSCLC二线治疗中培美曲塞优于吉非替尼（CTONG 0806研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e591260152f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543886, encodeId=ffe7154388690, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=ASCO 2013：二线治疗之Tivantinib的3期临床试验, objectType=article, longId=19771, objectId=9e6519e71bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e6519e71bd, replyNumber=0, likeNumber=85, createdTime=2013-06-08, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e6519e71bd, moduleTitle=ASCO 2013：二线治疗之Tivantinib的3期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e6519e71bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543885, encodeId=9cab1543885c9, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=ASCO 2013：培美曲塞二线治疗EGFR野生型NSCLC优于吉非替尼, objectType=article, longId=19770, objectId=349119e7046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=349119e7046, replyNumber=0, likeNumber=63, createdTime=2013-06-08, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=349119e7046, moduleTitle=ASCO 2013：培美曲塞二线治疗EGFR野生型NSCLC优于吉非替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=349119e7046)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543884, encodeId=a4f21543884be, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=JCO：香港中文大学莫树锦对比分析EGFR TKI药物一二线治疗情况, objectType=article, longId=19401, objectId=650819401a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=650819401a2, replyNumber=0, likeNumber=87, createdTime=2013-05-30, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=650819401a2, moduleTitle=JCO：香港中文大学莫树锦对比分析EGFR TKI药物一二线治疗情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=650819401a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543883, encodeId=0b6d1543883f4, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Lancet Oncol：阿西替尼可作为转移性肾细胞癌患者的二线治疗方案, objectType=article, longId=17730, objectId=efb91e73053, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efb91e73053, replyNumber=0, likeNumber=77, createdTime=2013-04-26, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efb91e73053, moduleTitle=Lancet Oncol：阿西替尼可作为转移性肾细胞癌患者的二线治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efb91e73053)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543882, encodeId=ef39154388235, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Lancet Oncol：晚期肝细胞癌二线治疗新药tivantinib, objectType=article, longId=11252, objectId=500a11252c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=500a11252c6, replyNumber=0, likeNumber=62, createdTime=2012-11-25, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=500a11252c6, moduleTitle=Lancet Oncol：晚期肝细胞癌二线治疗新药tivantinib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=500a11252c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543881, encodeId=2d61154388181, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Lancet：艾塞那肽用于糖尿病二线治疗效果佳, objectType=article, longId=7216, objectId=4cdde21679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cdde21679, replyNumber=0, likeNumber=77, createdTime=2012-06-21, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cdde21679, moduleTitle=Lancet：艾塞那肽用于糖尿病二线治疗效果佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cdde21679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543880, encodeId=c07515438801f, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=多西他赛+奈达铂二线治疗食管癌有效, objectType=article, longId=6413, objectId=6c4d6413f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c4d6413f2, replyNumber=0, likeNumber=67, createdTime=2012-05-23, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c4d6413f2, moduleTitle=多西他赛+奈达铂二线治疗食管癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c4d6413f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543879, encodeId=513215438e981, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=ASCO 2011: 氨柔比星二线治疗小细胞肺癌优于托泊替康, objectType=article, longId=2727, objectId=9d372e2759, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d372e2759, replyNumber=0, likeNumber=76, createdTime=2011-06-22, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d372e2759, moduleTitle=ASCO 2011: 氨柔比星二线治疗小细胞肺癌优于托泊替康, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d372e2759)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

二线治疗

2020-05-29

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

WCLC 2013：EGFR野生型NSCLC二线治疗中培美曲塞优于吉非替尼（CTONG 0806研究）

2013-11-01

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

ASCO 2013：二线治疗之Tivantinib的3期临床试验

2013-06-08

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

ASCO 2013：培美曲塞二线治疗EGFR野生型NSCLC优于吉非替尼

2013-06-08

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

JCO：香港中文大学莫树锦对比分析EGFR TKI药物一二线治疗情况

2013-05-30

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Lancet Oncol：阿西替尼可作为转移性肾细胞癌患者的二线治疗方案

2013-04-26

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Lancet Oncol：晚期肝细胞癌二线治疗新药tivantinib

2012-11-25

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Lancet：艾塞那肽用于糖尿病二线治疗效果佳

2012-06-21

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

多西他赛+奈达铂二线治疗食管癌有效

2012-05-23

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

ASCO 2011: 氨柔比星二线治疗小细胞肺癌优于托泊替康

2011-06-22

科室
- - 订阅+
  - 更多科室
工具
服务